The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
Market view
insulin aspart · Powder
2 marketed package NDCs · 2 active manufacturers
Most dispensed: 100 [iU]/mL · Injection, Suspension · #5 syringe, plastics/carton / 3 ml in 1 syringe, plastic · 100 [iU]/mL · Injection, Solution · #5 syringe, plastics/carton / 3 ml in 1 syringe, plastic · 100 [iU]/mL · Injection, Solution · #1 vial, glass/carton / 10 ml in 1 vial, glass · 100 [iU]/mL · Injection, Suspension · #1 vial, glass/carton / 10 ml in 1 vial, glass
What changed in the last 90 days
Every detected change for insulin aspart, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- NovologAug 19, 2026Price downNADAC $6.93804 → $6.93614 per unit (-0.03%)
- NovologAug 19, 2026Price downNADAC $8.93737 → $8.93569 per unit (-0.02%)
- NovoLog Mix 70/30Aug 19, 2026Price downNADAC $8.94106 → $8.93906 per unit (-0.02%)
- NovoLog Mix 70/30Aug 19, 2026Price downNADAC $6.92882 → $6.92777 per unit (-0.02%)
- NovologAug 19, 2026Price upNADAC $8.56966 → $8.57338 per unit (+0.04%)
- FiaspAug 19, 2026Price upNADAC $8.57252 → $8.57314 per unit (+0.01%)
- NovoLog Mix 70/30Jul 22, 2026Price downNADAC $8.94275 → $8.94106 per unit (-0.02%)
- NovologJul 22, 2026Price downNADAC $8.93837 → $8.93737 per unit (-0.01%)
- NovologJul 22, 2026Price downNADAC $6.93907 → $6.93804 per unit (-0.01%)
- NovologJul 22, 2026Price downNADAC $8.57149 → $8.56966 per unit (-0.02%)
Same drug class
Other molecules FDA puts in Insulin Analog, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- attention deficit mild drops· 1 maker
- attention deficit severe drops· 1 maker
- dna insulin drops· 1 maker
- insulin aspart injection· 1 maker
- insulin aspart-fsan· 1 maker
- insulin aspart-xjhz· 1 maker
- insulin degludec and liraglutide· 1 maker
- insulin glargine and lixisenatide· 1 maker
- insulin glargine-aldy· 1 maker
- insulin glulisine· 1 maker
- pancreas db liquescence· 1 maker
- insulin· 2 makers
Common questions
- Is Insulin aspart in shortage right now?
- No. FDA does not currently list Insulin aspart in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Insulin aspart?
- 7 companies have marketed Insulin aspart in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
- What does Insulin aspart cost?
- The typical pharmacy pays about $8.57 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.